M
Maarten Slagter
Researcher at Netherlands Cancer Institute
Publications - 13
Citations - 2946
Maarten Slagter is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 9, co-authored 11 publications receiving 1444 citations. Previous affiliations of Maarten Slagter include Leiden University.
Papers
More filters
Journal ArticleDOI
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids
Krijn K. Dijkstra,Chiara M Cattaneo,Fleur Weeber,Myriam Chalabi,Joris van de Haar,Lorenzo F. Fanchi,Maarten Slagter,Daphne L. van der Velden,Sovann Kaing,Sander Kelderman,Nienke van Rooij,Monique E. van Leerdam,Annekatrien Depla,Egbert F. Smit,Koen J. Hartemink,Rosa de Groot,Monika C. Wolkers,Norman Sachs,Petur Snaebjornsson,Kim Monkhorst,John B. A. G. Haanen,Hans Clevers,Ton N. Schumacher,Emile E. Voest +23 more
TL;DR: A platform to induce and analyze tumor-specific T cell responses to epithelial cancers in a personalized manner is established and co-cultures of autologous tumor organoids and peripheral blood lymphocytes can be used to enrich tumor-reactive T cells from peripheral blood of patients with mismatch repair-deficient colorectal cancer and non-small-cell lung cancer.
Journal ArticleDOI
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Leonie Voorwerk,Maarten Slagter,Hugo M. Horlings,Karolina Sikorska,Koen Van de Vijver,Koen Van de Vijver,Michiel de Maaker,Iris Nederlof,Roelof J.C. Kluin,Sarah Warren,SuFey Ong,T. Wiersma,Nicola S. Russell,Ferry Lalezari,Philip C. Schouten,Noor A. M. Bakker,Steven L. C. Ketelaars,Dennis Peters,Charlotte A.H. Lange,Erik van Werkhoven,Harm van Tinteren,I.A.M. Mandjes,Inge Kemper,Suzanne Onderwater,Myriam Chalabi,Sofie Wilgenhof,John B. A. G. Haanen,Roberto Salgado,Karin E. de Visser,Gabe S. Sonke,Lodewyk F. A. Wessels,Sabine C. Linn,Ton N. Schumacher,Christian U. Blank,Marleen Kok +34 more
TL;DR: A pick-the-winner clinical trial design in patients with metastatic triple-negative breast cancer shows that immune induction with doxorubicin or cisplatin may improve clinical responses to PD-1 blockade and induce a more favorable tumor microenvironment.
Journal ArticleDOI
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra,Chong Sun,Lucas T. Jae,Raquel Gomez-Eerland,Evert de Vries,Wei Wu,Meike Emma Willemijn Logtenberg,Maarten Slagter,Elisa A. Rozeman,Ingrid Hofland,Annegien Broeks,Hugo M. Horlings,Lodewyk F. A. Wessels,Christian U. Blank,Yanling Xiao,Albert J. R. Heck,Jannie Borst,Thijn R. Brummelkamp,Thijn R. Brummelkamp,Ton N. Schumacher +19 more
TL;DR: The data reveal that PD-L1 relies on CMTM6/4 to efficiently carry out its inhibitory function, and suggest potential new avenues to block this pathway.
Journal ArticleDOI
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
Daniel J. McGrail,Patrick G. Pilie,Naim U. Rashid,Leonie Voorwerk,Maarten Slagter,Marleen Kok,Eric Jonasch,Mustafa Khasraw,Amy B. Heimberger,Bora Lim,NT Ueno,Jennifer K. Litton,Renata Ferrarotto,Jeffrey T. Chang,S. L. Moulder,Sy Lin +15 more
TL;DR: In this article, the authors compared approaches to determine TMB and identify the correlation between predicted neoantigen load and CD8 T cells, and found that TMB-H tumors exhibited a 39.8% ORR to ICB [95% confidence interval (CI) 34.9-44.8], which was significantly higher than that observed in low TMB (TMB-L) tumors.
Journal ArticleDOI
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
Wouter Scheper,Sander Kelderman,Lorenzo F. Fanchi,Carsten Linnemann,Gavin M. Bendle,Marije A. J. de Rooij,Christian Hirt,Riccardo Mezzadra,Maarten Slagter,Krijn K. Dijkstra,Roelof J.C. Kluin,Petur Snaebjornsson,Katy Milne,Brad H. Nelson,Henry Zijlmans,Gemma G. Kenter,Emile E. Voest,John B. A. G. Haanen,Ton N. Schumacher +18 more
TL;DR: The intrinsic tumor reactivity of the intratumoral TCR repertoire of CD8+ T cells in ovarian and colorectal cancer is analyzed to indicate that the intrinsic capacity of intrumoral T cells to recognize adjacent tumor tissue can be rare and variable, and suggest that clinical efforts to reactivate intratumor T cells will benefit from approaches that simultaneously increase the quality of the intruder's TCR repertoires.